109744-49-2

Basic information

• Product Name: (3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester
• Synonyms: (3R)-3-[(TERT-BUTYLDIMETHYLSILYL)OXY] PENTANEDIOATE-1-METHYLMONOESTER;B-6;(3R)-3-[(terbutyldimethylsilyl)oxy]pentanedioate-1-methylmonoester;J-4：(3R)-3-[(tert-butyldimethylsilyl)oxy] pentanedioate-1-methylmonoester;(3R)-3-[(t-Butyldimethylsilyl)oxy]pentanedioate-1-methylmonoester,J-4;(3R)-3-[(tert-butyldimethylsily)oxy]pentanedioate-1-Methylmonoester;(R)-3-(tert-Butyl-dimethyl-silanyloxy)-pentanedioicacidmonomethylester;(R)-3-((tert-ButyldiMethylsilyl)oxy)-5-Methoxy-5-oxopentanoic acid
• CAS NO: 109744-49-2
• Molecular Formula: C₁₂H₂₄O₅Si
• Molecular Weight: 276.4
• EINECS: 1312995-182-4
• Product Categories: rosuvastatin intermediates
• Mol File: 109744-49-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 327.412 °C at 760 mmHg
• Flash Point: 151.814 °C
• Appearance: /
• Density: 1.034 cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.447
• PKA: 4.11±0.10(Predicted)
• CAS DataBase Reference: (3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester(CAS DataBase Reference)
• NIST Chemistry Reference: (3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester(109744-49-2)
• EPA Substance Registry System: (3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester(109744-49-2)

Safety Data

• Hazardous Substances Data: 109744-49-2(Hazardous Substances Data)

Usage

General Description

The chemical "(3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester" is an organic compound with a complex structure. It contains a (3R)-3-(tert-butyldimethylsilyl)oxy group as well as a pentanedioate-1-methyl monoester moiety. The tert-butyldimethylsilyl group is a protecting group often used in organic synthesis, while the pentanedioate-1-methyl monoester moiety suggests the presence of a pentanedioic acid derivative. (3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester is likely to have applications in organic synthesis, particularly in the protection and manipulation of functional groups. Its precise function and potential uses would depend on its specific chemical properties and reactivity.

InChI:InChI=1/C12H24O5Si/c1-12(2,3)18(5,6)17-9(7-10(13)14)8-11(15)16-4/h9H,7-8H2,1-6H3,(H,13,14)/t9-/m1/s1

Upstream product

• 67-56-1 methanol 
• 131466-61-0 (3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester 
• 32328-03-3 diethyl 3-hydroxyglutarate 
• 91424-39-4 3-[[(1,1-Dimethylethyl)dimethylsilyl]-oxy]pentanedioic acid,diethyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 124-41-4 sodium methylate 
• 121980-45-8 (3R)-(-)-methyl 3-<(tert-butyldimethylsilyl)oxy>-4-formylbutanoate 
• 140164-51-8 methyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxane-4-yl)acetate 
• 91424-40-7 3-(tert-butyldimethylsilyloxy)glutaric anhydride 
• 1350364-00-9 hydrogen (3R)-1-methyl 3-[(tert-butyldimethylsilyl)-oxy]pentanedioate cyclohexylamine salt 
• 7250-55-7 dimethyl 3-hydroxypentanedioate 
• 96555-56-5 (3S,1'S)-methyl 1'-phenylethyl 3-<(tert-butyldimethylsilyl)oxy>pentanedioate 
• 90613-44-8 methyl 3-acetoxypentanedioate 

Downstream Products

• 147118-35-2 methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate 
• 1350364-18-9 C₁₅H₂₈O₇Si 
• 1350364-05-4 hydrogen (3R)-1-methyl 3-[(tert-butyldimethylsilyl)-oxy]pentanedioate benzylamine salt 
• 1350364-00-9 hydrogen (3R)-1-methyl 3-[(tert-butyldimethylsilyl)-oxy]pentanedioate cyclohexylamine salt 
• 147118-39-6 methyl (3R,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3-hydroxy-5-oxohept-6-enoate 
• 182075-76-9 (R,E)-methyl 3-(tert-butyldimethylsilyloxy)-7-(2-cyclopropyl-4-(-4-fluorophenyl)-quinolin-3-yl)-5-oxohept-6-enoate 
• 917752-45-5 methyl (E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-3-hydroxy-5-oxo-6-heptenate 
• 1622873-98-6 C₃₂H₄₈FN₃O₆SSi 

Relevant articles and documents

Preparation method of high-purity statin drug intermediate

The invention relates to a preparation method of a high-purity statin drug intermediate. The preparation method is characterized in that 3-hydroxyl ethyl glutarate is used as the initial raw material to prepare (3R)-tert-butyl dimethyl silyloxy-5-oxo-6-triphenyl phosphine caproate (abbreviated as J6) through substitution reaction, hydrolysis reaction, cyclization reaction, resolution reaction, hydrogenation reaction, acylation reaction and Wittig reaction. The preparation method is mild in condition, stable in process, cheap in raw material, easy in raw material obtaining, easy in three-waste treatment, low in preparation cost, high in product purity and suitable for industrial production.

Engineering of the Conformational Dynamics of Lipase to Increase Enantioselectivity

In order to increase the R-enantioselectivity of Candida antarctica lipase B (CALB) toward (R)-3-t-butyl-dimethyl-silyloxy glutaric acid methyl monoester at 30 °C, we engineered CALB conformational dynamics. Based on structural analysis and molecular dynamics simulations, two key residues (D223 and A281) were identified, and three mutants (D223V, A281S, and D223V/A281S) were designed to decrease the conformational dynamics of the pocket and channel. Computational and experimental evaluations were performed for all mutants, with the D223V/A281S mutant exhibiting high R-enantioselectivity (>99.00%; increased from 8.00%) and high space-time yield (107.54 g L-1 d-1 a 5.70-fold increase).

AN IMPROVED PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF HMG-COA REDUCTASE INHIBITORS

The present invention relates to an improved process for the preparation of intermediates of HMG-CoA reductase inhibitors of Formulae-IXa or IXb and further conversion to HMG-CoA reductase inhibitors and pharmaceutically acceptable salts thereof.